NASDAQ:ACXP Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis $0.47 -0.01 (-2.20%) Closing price 04:00 PM EasternExtended Trading$0.47 -0.01 (-1.15%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Acurx Pharmaceuticals Stock (NASDAQ:ACXP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Acurx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.45▼$0.5150-Day Range$0.31▼$0.8252-Week Range$0.30▼$3.33Volume691,746 shsAverage Volume1.66 million shsMarket Capitalization$11.07 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company Overview Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. Read More Acurx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreACXP MarketRank™: Acurx Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 502nd out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Acurx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Acurx Pharmaceuticals are expected to decrease in the coming year, from ($0.89) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acurx Pharmaceuticals is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acurx Pharmaceuticals is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcurx Pharmaceuticals has a P/B Ratio of 15.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Acurx Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.59% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently increased by 78.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcurx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcurx Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.59% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently increased by 78.44%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.30 News SentimentAcurx Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Acurx Pharmaceuticals this week, compared to 1 article on an average week.Search Interest9 people have searched for ACXP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders26.00% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.53% of the stock of Acurx Pharmaceuticals is held by institutions.Read more about Acurx Pharmaceuticals' insider trading history. Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACXP Stock News HeadlinesAcurx Pharmaceuticals Inc Ordinary Shares ACXP - MorningstarJuly 2, 2025 | morningstar.comMAcurx Pharmaceuticals LLC (ACXP) - Investing.comJuly 2, 2025 | investing.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 7 at 2:00 AM | Paradigm Press (Ad)/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ | ACXP Stock NewsJune 18, 2025 | gurufocus.comAcurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2. ...June 17, 2025 | gurufocus.comAcurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross ProceedsJune 17, 2025 | investing.comAcurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross ProceedsJune 17, 2025 | prnewswire.comAcurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDIJune 17, 2025 | prnewswire.comSee More Headlines ACXP Stock Analysis - Frequently Asked Questions How have ACXP shares performed this year? Acurx Pharmaceuticals' stock was trading at $0.8140 at the beginning of 2025. Since then, ACXP shares have decreased by 42.1% and is now trading at $0.4714. How were Acurx Pharmaceuticals' earnings last quarter? Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) announced its earnings results on Monday, May, 12th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. Read the conference call transcript. When did Acurx Pharmaceuticals IPO? Acurx Pharmaceuticals (ACXP) raised $15 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO. How do I buy shares of Acurx Pharmaceuticals? Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acurx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acurx Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), PayPal (PYPL), Adverum Biotechnologies (ADVM), Rolls-Royce Holdings PLC (RYCEY), Shopify (SHOP), AbCellera Biologics (ABCL) and atai Life Sciences (ATAI). Company Calendar Last Earnings5/12/2025Today7/07/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACXP CIK1736243 Webwww.acurxpharma.com Phone917-533-1469FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,616.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.10 million Net MarginsN/A Pretax MarginN/A Return on Equity-526.78% Return on Assets-223.78% Debt Debt-to-Equity RatioN/A Current Ratio1.93 Quick Ratio1.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book15.53Miscellaneous Outstanding Shares23,480,000Free Float17,377,000Market Cap$10.94 million OptionableOptionable Beta-1.23 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:ACXP) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.